These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. Sousa TR; Rema J; Machado S; Novais F Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736 [TBL] [Abstract][Full Text] [Related]
44. Do the therapeutic effects of psilocybin involve actions in the gut? Reed F; Foldi CJ Trends Pharmacol Sci; 2024 Feb; 45(2):107-117. PubMed ID: 38216431 [TBL] [Abstract][Full Text] [Related]
45. Psychedelia: The interplay of music and psychedelics. Jerotic K; Vuust P; Kringelbach ML Ann N Y Acad Sci; 2024 Jan; 1531(1):12-28. PubMed ID: 37983198 [TBL] [Abstract][Full Text] [Related]
47. Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice. Qu Y; Chang L; Ma L; Wan X; Hashimoto K Pharmacol Biochem Behav; 2023 Jan; 222():173500. PubMed ID: 36476377 [TBL] [Abstract][Full Text] [Related]
48. A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression. Pilozzi A; Foster S; Mischoulon D; Fava M; Huang X Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569888 [TBL] [Abstract][Full Text] [Related]
49. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. Ling S; Ceban F; Lui LMW; Lee Y; Teopiz KM; Rodrigues NB; Lipsitz O; Gill H; Subramaniapillai M; Mansur RB; Lin K; Ho R; Rosenblat JD; Castle D; McIntyre RS CNS Drugs; 2022 Jan; 36(1):17-30. PubMed ID: 34791625 [TBL] [Abstract][Full Text] [Related]
50. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002 [TBL] [Abstract][Full Text] [Related]
51. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Jefferson SJ; Gregg I; Dibbs M; Liao C; Wu H; Davoudian PA; Woodburn SC; Wehrle PH; Sprouse JS; Sherwood AM; Kaye AP; Pittenger C; Kwan AC Neuropsychopharmacology; 2023 Aug; 48(9):1257-1266. PubMed ID: 37015972 [TBL] [Abstract][Full Text] [Related]
52. Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. Kadriu B; Greenwald M; Henter ID; Gilbert JR; Kraus C; Park LT; Zarate CA Int J Neuropsychopharmacol; 2021 Jan; 24(1):8-21. PubMed ID: 33252694 [TBL] [Abstract][Full Text] [Related]
53. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Aleksandrova LR; Phillips AG Trends Pharmacol Sci; 2021 Nov; 42(11):929-942. PubMed ID: 34565579 [TBL] [Abstract][Full Text] [Related]
54. Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. Wulff AB; Nichols CD; Thompson SM Neuropharmacology; 2023 Jun; 231():109504. PubMed ID: 36921889 [TBL] [Abstract][Full Text] [Related]
55. A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics. Savalia NK; Shao LX; Kwan AC Trends Neurosci; 2021 Apr; 44(4):260-275. PubMed ID: 33358035 [TBL] [Abstract][Full Text] [Related]